Company Description
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia.
The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder.
It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Timothy Dyer |
Contact Details
Address: Chemin des Mines, 9 Geneva, 1202 Switzerland | |
| Phone | 41 22 884 1555 |
| Website | addextherapeutics.com |
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J107 |
| ISIN Number | US00654J2069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer and Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer and Director |
| Lénaic Teyssédou | Head of Finance |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 6-K | Report of foreign issuer |
| Jun 25, 2025 | 6-K | Report of foreign issuer |
| Jun 23, 2025 | SCHEDULE 13D/A | Filing |
| Jun 20, 2025 | 6-K | Report of foreign issuer |
| Jun 6, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | 20-F | Annual and transition report of foreign private issuers |
| May 12, 2025 | 6-K | Report of foreign issuer |
| Apr 30, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 30, 2025 | 6-K | Report of foreign issuer |
| Apr 25, 2025 | 6-K | Report of foreign issuer |